yellow fever

Summary

Summary: An acute infectious disease primarily of the tropics, caused by a virus and transmitted to man by mosquitoes of the genera Aedes and Haemagogus. The severe form is characterized by fever, HEMOLYTIC JAUNDICE, and renal damage.

Top Publications

  1. Pfister M, Kürsteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg. 2005;72:339-46 pubmed
    BERNA-YF (Flavimun) is a live, attenuated yellow fever (YF) vaccine of the 17D strain produced by Berna Biotech Ltd. following a transfer of technology from the Robert Koch Institute (RKI) in Berlin, Germany...
  2. Rifakis P, Benitez J, De la Paz Pineda J, Rodriguez Morales A. Epizootics of yellow fever in Venezuela (2004-2005): an emerging zoonotic disease. Ann N Y Acad Sci. 2006;1081:57-60 pubmed
    Epidemics and epizootics of yellow fever (YF) have been occurring in the border area of eastern Colombia and western Venezuela since 2003; for this reason many epidemiological control measures were adopted by the Ministry of Health (MOH) ..
  3. Monath T, Lee C, Julander J, Brown A, Beasley D, Watts D, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010;28:3827-40 pubmed publisher
    In the last 10 years new concerns have arisen about safety of the live, attenuated yellow fever (YF) 17D vaccine, in particular viscerotropic adverse events, which have a case-fatality rate of 64%...
  4. Amaku M, Coutinho F, Massad E. Why dengue and yellow fever coexist in some areas of the world and not in others?. Biosystems. 2011;106:111-20 pubmed publisher
    Urban yellow fever and dengue coexist in Africa but not in Asia and South America...
  5. Domingo C, Escadafal C, Rumer L, Mendez J, García P, Sall A, et al. First international external quality assessment study on molecular and serological methods for yellow fever diagnosis. PLoS ONE. 2012;7:e36291 pubmed publisher
    ..The results indicate the need for improving serological and molecular diagnosis techniques and provide a follow-up of the diagnostic profiles. ..
  6. Ono L, Wollinger W, Rocco I, Coimbra T, Gorin P, Sierakowski M. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antiviral Res. 2003;60:201-8 pubmed
    ..50, and an average molecular weight of 620x10(3) and 574x10(3) gmol(-1), respectively. Their activities against yellow fever virus (YFV; BeH111 strain) and dengue 1 virus (DEN-1; Hawaii strain) were evaluated...
  7. Bryant J, Vasconcelos P, Rijnbrand R, Mutebi J, Higgs S, Barrett A. Size heterogeneity in the 3' noncoding region of South American isolates of yellow fever virus. J Virol. 2005;79:3807-21 pubmed
    ..Previous studies of yellow fever virus (YFV) and dengue virus have found that modifications to the 3' NCR are sometimes associated with ..
  8. Gómez S, Ocazionez R. [Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue]. Rev Salud Publica (Bogota). 2008;10:796-807 pubmed
    Determining the frequency of yellow fever seroprotective antibody neutralising titres (YF-NT >or=1:10) in Colombians vaccinated with the 17 D virus and ascertaining the extent to which YF virus can be neutralised by dengue antibodies...
  9. Calvo E, Mizurini D, Sa Nunes A, Ribeiro J, Andersen J, Mans B, et al. Alboserpin, a factor Xa inhibitor from the mosquito vector of yellow fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity. J Biol Chem. 2011;286:27998-8010 pubmed publisher
    ..of factor Xa (FXa) inhibition by Alboserpin, the major salivary gland anticoagulant from the mosquito and yellow fever vector Aedes albopictus, has been characterized...

More Information

Publications104 found, 100 shown here

  1. Campi Azevedo A, de Araújo Porto L, Luiza Silva M, Batista M, Martins M, Sathler Avelar R, et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS ONE. 2012;7:e49828 pubmed publisher
    ..immune response in children submitted to primary vaccination with the YF-17D-213/77 or YF-17DD yellow fever (YF) substrains...
  2. Auguste A, Lemey P, Pybus O, Suchard M, Salas R, Adesiyun A, et al. Yellow fever virus maintenance in Trinidad and its dispersal throughout the Americas. J Virol. 2010;84:9967-77 pubmed publisher
    Trinidad, like many other American regions, experiences repeated epizootics of yellow fever virus (YFV)...
  3. Staples J, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1-27 pubmed
    This report updates CDC's recommendations for using yellow fever (YF) vaccine (CDC. Yellow fever vaccine: recommendations of the Advisory Committee on Immunizations Practices: MMWR 2002;51[No. RR-17])...
  4. Barwick Eidex R. History of thymoma and yellow fever vaccination. Lancet. 2004;364:936 pubmed
  5. Ergunay K, Saygan M, Aydogan S, Litzba N, Niedrig M, Pinar A, et al. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey]. Mikrobiyol Bul. 2010;44:415-24 pubmed
    Dengue virus (DENV) and yellow fever virus (YFV) are two of the globally prevalent vector-borne flaviviruses...
  6. Wamala J, Malimbo M, Okot C, Atai Omoruto A, Tenywa E, Miller J, et al. Epidemiological and laboratory characterization of a yellow fever outbreak in northern Uganda, October 2010-January 2011. Int J Infect Dis. 2012;16:e536-42 pubmed publisher
    ..Overall, 181 cases met the yellow fever (YF) suspected case definition; there were 45 deaths (case fatality rate 24.9%). Only 13 (7...
  7. Dube F, Tadesse K, Birgersson G, Seyoum E, Tekie H, Ignell R, et al. Fresh, dried or smoked? Repellent properties of volatiles emitted from ethnomedicinal plant leaves against malaria and yellow fever vectors in Ethiopia. Malar J. 2011;10:375 pubmed publisher
  8. Thibodeaux B, Garbino N, Liss N, Piper J, Blair C, Roehrig J. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine. 2012;30:3180-7 pubmed publisher
    b>Yellow fever virus (YFV), a member of the genus Flavivirus, is a mosquito-borne pathogen that requires wild-type (wt), virulent strains to be handled at biosafety level (BSL) 3, with HEPA-filtration of room air exhaust (BSL3+)...
  9. Sallis E, de Barros V, Garmatz S, Fighera R, Graca D. A case of yellow fever in a brown howler (Alouatta fusca) in Southern Brazil. J Vet Diagn Invest. 2003;15:574-6 pubmed
    ..According to clinical signs, and necropsy and histopathology findings, yellow fever virus (YFV) infection was suspected...
  10. Bae H, Drosten C, Emmerich P, Colebunders R, Hantson P, Pest S, et al. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol. 2005;33:274-80 pubmed
    b>Yellow fever remains one of the great burdens for public health in the endemic regions in Africa and South America...
  11. Heinz F, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine. 2012;30:4301-6 pubmed publisher
    Several human-pathogenic flaviviruses (including yellow fever, dengue, Japanese encephalitis, West Nile and tick-borne encephalitis viruses) have a significant public health impact in different parts of the world and the potential of ..
  12. Monath T, Barrett A. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343-95 pubmed
  13. Freire M, Mann G, Marchevsky R, Yamamura A, Almeida L, Jabor A, et al. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity. Vaccine. 2005;23:2501-12 pubmed
    While a good vaccine against yellow fever (YF) virus has been available for decades, the basic technology for the production of YF vaccine in chicken embryos has remained substantially unchanged since the 1940s...
  14. Lindsey N, Schroeder B, Miller E, Braun M, Hinckley A, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077-82 pubmed publisher
    b>Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety...
  15. Cardoso J, de Almeida M, dos Santos E, da Fonseca D, Sallum M, Noll C, et al. Yellow fever virus in Haemagogus leucocelaenus and Aedes serratus mosquitoes, southern Brazil, 2008. Emerg Infect Dis. 2010;16:1918-24 pubmed publisher
    b>Yellow fever virus (YFV) was isolated from Haemagogus leucocelaenus mosquitoes during an epizootic in 2001 in the Rio Grande do Sul State in southern Brazil...
  16. Quaresma J, Barros V, Fernandes E, Pagliari C, Guedes F, da Costa Vasconcelos P, et al. Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res. 2006;116:91-7 pubmed
    b>Yellow fever is an infectious, non-contagious disease caused by an RNA virus of the family Flaviviridae, which is transmitted to man by the bite of hematophagous mosquitoes...
  17. Hayes E. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg. 2007;101:967-71 pubmed
    Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine...
  18. Johansson M, Arana Vizcarrondo N, Biggerstaff B, Gallagher N, Marano N, Staples J. Assessing the risk of international spread of yellow fever virus: a mathematical analysis of an urban outbreak in Asuncion, 2008. Am J Trop Med Hyg. 2012;86:349-58 pubmed publisher
    b>Yellow fever virus (YFV), a mosquito-borne virus endemic to tropical Africa and South America, is capable of causing large urban outbreaks of human disease...
  19. Bryant J, Barrett A. Comparative phylogenies of yellow fever isolates from Peru and Brazil. FEMS Immunol Med Microbiol. 2003;39:103-18 pubmed
    We recently reported phylogenetic evidence to support the presence of enzootic transmission foci of yellow fever virus (YFV) in Peru [Bryant et al., Emerg. Infect. Dis. (2003)]...
  20. Monath T. Treatment of yellow fever. Antiviral Res. 2008;78:116-24 pubmed
    b>Yellow fever (YF) is a life-threatening mosquito-borne flaviviral hemorrhagic fever (VHF) characterized by severe hepatitis, renal failure, hemorrhage, and rapid terminal events with shock and multi-organ failure...
  21. Monath T. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot. 2006;99:341-7 pubmed
    b>Yellow fever is a potentially fatal viral hemorrhagic fever...
  22. Maciel M, Kellathur S, Chikhlikar P, Dhalia R, Sidney J, Sette A, et al. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology. 2008;378:105-17 pubmed publisher
    ..We inoculated BALB/c (H2d) mice with 17DD yellow fever vaccine to investigate the correlations between approaches used for epitope discovery: ELISPOT assays, binding ..
  23. Barnett E. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-6 pubmed
    b>Yellow fever continues to occur in regions of Africa and South America, despite the availability of effective vaccines...
  24. Belmusto Worn V, Sanchez J, McCarthy K, Nichols R, Bautista C, Magill A, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005;72:189-97 pubmed
    We conducted a randomized, double-blind, phase III yellow fever (YF) vaccine trial among 1,107 healthy children in Sullana in northern Peru...
  25. Veit O, Niedrig M, Chapuis Taillard C, Cavassini M, Mossdorf E, Schmid P, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659-66 pubmed publisher
    b>Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)-infected patients, and adequate immunogenicity and safety are of concern in this population...
  26. Gubler D. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?. Comp Immunol Microbiol Infect Dis. 2004;27:319-30 pubmed
    b>Yellow fever and dengue are old diseases, having caused major epidemics in centuries past...
  27. Onyango C, Grobbelaar A, Gibson G, Sang R, Sow A, Swaneopel R, et al. Yellow fever outbreak, southern Sudan, 2003. Emerg Infect Dis. 2004;10:1668-70 pubmed
    In May 2003, an outbreak of fatal hemorrhagic fever, caused by yellow fever virus, occurred in southern Sudan...
  28. Julander J, Furuta Y, Shafer K, Sidwell R. Activity of T-1106 in a hamster model of yellow Fever virus infection. Antimicrob Agents Chemother. 2007;51:1962-6 pubmed
    b>Yellow fever virus (YFV) causes 30,000 deaths worldwide, despite the availability of a vaccine...
  29. Julander J, Shafer K, Smee D, Morrey J, Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009;53:202-9 pubmed publisher
    Treatment with the nucleoside analog T-1106 was previously shown to be effective in a hamster model of yellow fever virus (YFV) disease, even though it had only slight activity in cell culture...
  30. Carrington C, Auguste A. Evolutionary and ecological factors underlying the tempo and distribution of yellow fever virus activity. Infect Genet Evol. 2013;13:198-210 pubmed publisher
    b>Yellow fever virus (YFV) is historically one of the most important viruses to affect human populations...
  31. Gandini M, Reis S, Torrentes Carvalho A, Azeredo E, Freire M, Galler R, et al. Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-? and IFN-? profiles. Mem Inst Oswaldo Cruz. 2011;106:594-605 pubmed
    Flaviviruses cause severe acute febrile and haemorrhagic infections, including dengue and yellow fever and the pathogenesis of these infections is caused by an exacerbated immune response...
  32. Monath T. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11:427-48 pubmed publisher
    The live, attenuated yellow fever (YF) 17D vaccine provides highly effective and durable immunity and is widely used for travelers to and residents of endemic areas of South America and Africa...
  33. Whittembury A, Ramirez G, Hernandez H, Ropero A, Waterman S, Ticona M, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27:5974-81 pubmed publisher
    Five suspected cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) clustered in space and time following a vaccination campaign in Ica, Peru in 2007...
  34. Akondy R, Monson N, Miller J, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183:7919-30 pubmed publisher
    The live yellow fever vaccine (YF-17D) offers a unique opportunity to study memory CD8(+) T cell differentiation in humans following an acute viral infection...
  35. Ishida Y, Chen A, Tsuruda J, Cornel A, Debboun M, Leal W. Intriguing olfactory proteins from the yellow fever mosquito, Aedes aegypti. Naturwissenschaften. 2004;91:426-31 pubmed
    Four antennae-specific proteins (AaegOBP1, AaegOBP2, AaegOBP3, and AaegASP1) were isolated from the yellow fever mosquito, Aedes aegypti and their full-length cDNAs were cloned...
  36. Lefeuvre A, Contamin H, Decelle T, Fournier C, Lang J, Deubel V, et al. Host-cell interaction of attenuated and wild-type strains of yellow fever virus can be differentiated at early stages of hepatocyte infection. Microbes Infect. 2006;8:1530-8 pubmed
    b>Yellow fever (YF) virus is currently found in tropical Africa and South America, and is responsible for a febrile to severe illness characterized by organ failure and shock...
  37. Cooper D, Thi E, Chamberlain C, Pio F, Lowenberger C. Aedes Dronc: a novel ecdysone-inducible caspase in the yellow fever mosquito, Aedes aegypti. Insect Mol Biol. 2007;16:563-72 pubmed
    ..Here, we describe the characterization of Aedes Dronc, a novel caspase in the yellow fever mosquito, Aedes aegypti...
  38. de Souza R, Foster P, Sallum M, Coimbra T, Maeda A, Silveira V, et al. Detection of a new yellow fever virus lineage within the South American genotype I in Brazil. J Med Virol. 2010;82:175-85 pubmed publisher
    Nucleotide sequences of two regions of the genomes of 11 yellow fever virus (YFV) samples isolated from monkeys or humans with symptomatic yellow fever (YF) in Brazil in 2000, 2004, and 2008 were determined with the objective of ..
  39. Traiber C, Coelho Amaral P, Ritter V, Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J). 2011;87:269-72 pubmed publisher
    To describe a case of infant meningoencephalitis that was probably caused by yellow fever vaccine virus transmitted via breastmilk.
  40. Bernáth B, Horvath G, Meyer Rochow V. Polarotaxis in egg-laying yellow fever mosquitoes Aedes (Stegomyia) aegypti is masked due to infochemicals. J Insect Physiol. 2012;58:1000-6 pubmed publisher
    ..The yellow fever mosquito Aedes (Stegomyia) aegypti has been thought to be an exception, locating its breeding habitats by ..
  41. Engel A, Vasconcelos P, McArthur M, Barrett A. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine. 2006;24:2803-9 pubmed
    Although the live attenuated yellow fever (YF) 17D vaccine is considered to be one of the safest vaccines in the world today, several cases of disease associated with administration of the vaccine have been reported, including YF vaccine-..
  42. Gould E, Solomon T. Pathogenic flaviviruses. Lancet. 2008;371:500-9 pubmed publisher
    ..of diseases in human beings after infections by mosquito-borne or tick-borne flaviviruses such as yellow fever, dengue, West Nile, St Louis encephalitis, Japanese encephalitis, tick-borne encephalitis, Kyasanur Forest ..
  43. Staples J, Monath T. Yellow fever: 100 years of discovery. JAMA. 2008;300:960-2 pubmed publisher
  44. Dekker T, Cardé R. Moment-to-moment flight manoeuvres of the female yellow fever mosquito (Aedes aegypti L.) in response to plumes of carbon dioxide and human skin odour. J Exp Biol. 2011;214:3480-94 pubmed publisher
    ..Apparently, yellow fever mosquitoes need longer continuous exposure to complex skin-odour blends to induce activation and source finding.
  45. Lourenco de Oliveira R, Vazeille M, de Filippis A, Failloux A. Aedes aegypti in Brazil: genetically differentiated populations with high susceptibility to dengue and yellow fever viruses. Trans R Soc Trop Med Hyg. 2004;98:43-54 pubmed
    ..Dengue outbreaks have occurred since 1981 and became endemic in several cities in Brazil after 1986. Urban yellow fever has not occurred since 1942, and only jungle yellow fever cases have been reported...
  46. Camacho L, de Aguiar S, Freire M, Leal M, do Nascimento J, Iguchi T, et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica. 2005;39:413-20 pubmed
    To compare the reactogenicity of three yellow fever (YF) vaccines from WHO-17D and Brazilian 17DD substrains (different seed-lots) and placebo.
  47. von Lindern J, Aroner S, Barrett N, Wicker J, Davis C, Barrett A. Genome analysis and phylogenetic relationships between east, central and west African isolates of Yellow fever virus. J Gen Virol. 2006;87:895-907 pubmed
    b>Yellow fever virus (YFV), a reemerging disease agent in Africa and South America, is the prototype member of the genus Flavivirus...
  48. Gaspar L, Mendes Y, Yamamura A, Almeida L, Caride E, Gonçalves R, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods. 2008;150:57-62 pubmed publisher
    The successful Yellow Fever (YF) vaccine consists of the live attenuated 17D-204 or 17DD viruses...
  49. Farnon E, Gould L, Griffith K, Osman M, Kholy A, Brair M, et al. Household-based sero-epidemiologic survey after a yellow fever epidemic, Sudan, 2005. Am J Trop Med Hyg. 2010;82:1146-52 pubmed publisher
    From September through early December 2005, an outbreak of yellow fever (YF) occurred in South Kordofan, Sudan, resulting in a mass YF vaccination campaign...
  50. Moreno E, Rocco I, Bergo E, Brasil R, Siciliano M, Suzuki A, et al. Reemergence of yellow fever: detection of transmission in the State of São Paulo, Brazil, 2008. Rev Soc Bras Med Trop. 2011;44:290-6 pubmed
    Following yellow fever virus (YFV) isolation in monkeys from the São José do Rio Preto region and two fatal human autochthonous cases from the Ribeirão Preto region, State of São Paulo, Brazil, two expeditions for entomological ..
  51. Ponnusamy L, Böröczky K, Wesson D, Schal C, Apperson C. Bacteria stimulate hatching of yellow fever mosquito eggs. PLoS ONE. 2011;6:e24409 pubmed publisher
  52. Zhong D, Menge D, Temu E, Chen H, Yan G. Amplified fragment length polymorphism mapping of quantitative trait loci for malaria parasite susceptibility in the yellow fever mosquito Aedes aegypti. Genetics. 2006;173:1337-45 pubmed
    The yellow fever mosquito Aedes aegypti has been the subject of extensive genetic research due to its medical importance and the ease with which it can be manipulated in the laboratory...
  53. Barban V, Girerd Y, Aguirre M, Gulia S, Pétiard F, Riou P, et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine. 2007;25:2941-50 pubmed
    We have retrospectively analyzed 12 bulk lots of yellow fever vaccine Stamaril, produced between 1990 and 2002 and prepared from the same seed lot that has been in continuous use since 1990...
  54. Barrett A, Teuwen D. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol. 2009;21:308-13 pubmed publisher
    b>Yellow fever 17D vaccine is one of the most successful vaccines ever developed and over 540 million doses have been used. Nevertheless there has been very little known about the mechanism of protection induced by the vaccine...
  55. Reiter P. Yellow fever and dengue: a threat to Europe?. Euro Surveill. 2010;15:19509 pubmed
    ..The history of yellow fever and dengue in temperate regions confirms that transmission of both diseases could recur, particularly if Ae...
  56. Thomas R, Lorenzetti D, Spragins W, Jackson D, Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine. 2011;29:4544-55 pubmed publisher
    To identify the rate of serious adverse events attributable to yellow fever vaccination with 17D and 17DD strains reported in active and passive surveillance data.
  57. Grant A, Dickens J. Functional characterization of the octenol receptor neuron on the maxillary palps of the yellow fever mosquito, Aedes aegypti. PLoS ONE. 2011;6:e21785 pubmed publisher
    ..Lesser responses were elicited by stimulation with the (S)-enantiomer and various structural analogs...
  58. Jentes E, Poumerol G, Gershman M, Hill D, Lemarchand J, Lewis R, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11:622-32 pubmed publisher
    The changing epidemiology of yellow fever and continued reports of rare but serious adverse events associated with yellow fever vaccine have drawn attention to the need to revisit criteria for the designation of areas with risk for yellow ..
  59. McMullan L, Frace M, Sammons S, Shoemaker T, Balinandi S, Wamala J, et al. Using next generation sequencing to identify yellow fever virus in Uganda. Virology. 2012;422:1-5 pubmed publisher
    ..of total RNA extracted directly from patient sera and next generation sequencing resulted in detection of yellow fever virus and generation of 98% of the virus genome sequence...
  60. Barrett A, Monath T. Epidemiology and ecology of yellow fever virus. Adv Virus Res. 2003;61:291-315 pubmed
  61. Vasconcelos P, Bryant J, da Rosa T, Tesh R, Rodrigues S, Barrett A. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis. 2004;10:1578-84 pubmed
    An analysis of 79 yellow fever virus (YFV) isolates collected from 1935 to 2001 in Brazil showed a single genotype (South America I) circulating in the country, with the exception of a single strain from Rondonia, which represented South ..
  62. Marfin A, Eidex R, Kozarsky P, Cetron M. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am. 2005;19:151-68, ix pubmed
    Appropriate administration of yellow fever or Japanese encephalitis vaccines to travelers requires an assessment of the traveler's risk for infection with these vector-borne flaviviruses during their travels and the presence of risk ..
  63. Moffett S, Moffett D. Comparison of immunoreactivity to serotonin, FMRFamide and SCPb in the gut and visceral nervous system of larvae, pupae and adults of the yellow fever mosquito Aedes aegypti. J Insect Sci. 2005;5:20 pubmed
    ..Another focus of control is the pyloric valve, which is encircled by axon-like processes. The immunoreactive pattern of this region differs across life stages, expressing SCP-I in larvae, S-I in pupae, and both SCP-I and RF-I in adults...
  64. Monath T. Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007;357:2222-5 pubmed
  65. Roukens A, Visser L. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008;8:1787-95 pubmed
    b>Yellow fever is a re-emerging infectious disease, as vector control and routine immunisation have dwindled in endemic areas in the last few decades...
  66. Nascimento Silva J, Camacho L, Siqueira M, Freire M, Castro Y, Maia M, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29:6327-34 pubmed publisher
    A randomized trial was conducted to assess the immunogenicity and reactogenicity of yellow fever vaccines (YFV) given either simultaneously in separate injections, or 30 days or more after a combined measles-mumps-rubella (MMR) vaccine...
  67. Tetreau G, Bayyareddy K, Jones C, Stalinski R, Riaz M, Paris M, et al. Larval midgut modifications associated with Bti resistance in the yellow fever mosquito using proteomic and transcriptomic approaches. BMC Genomics. 2012;13:248 pubmed
    ..gene transcription using DNA microarray and RT-qPCR and 2. differential expression of brush border membrane proteins using DIGE (Differential In Gel Electrophoresis)...
  68. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine. 2004;22:2103-5 pubmed
    b>Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries...
  69. Fitzner J, Coulibaly D, Kouadio D, Yavo J, Loukou Y, Koudou P, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine. 2004;23:156-62 pubmed
    In 2001, a vaccination campaign against yellow fever was carried out in Abidjan, Cote d'Ivoire. During the campaign and 4 weeks after an active surveillance system for adverse events following immunization (AEFI) was set up. More then 2...
  70. Vellozzi C, Mitchell T, Miller E, Casey C, Eidex R, Hayes E. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg. 2006;75:333-6 pubmed
    During 1996 through 2004, 29 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been reported worldwide; 17 were fatal...
  71. Fernandes G, Camacho L, Sá Carvalho M, Batista M, de Almeida S. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine. 2007;25:3124-8 pubmed
    ..presents an analysis of notified AEFI cases between 1999 and 2005 and their temporal association with 2001 yellow fever vaccination campaign, AEFI notification attributed to yellow fever vaccination rose from 0.06 to 1...
  72. Domingo C, Niedrig M. Safety of 17D derived yellow fever vaccines. Expert Opin Drug Saf. 2009;8:211-21 pubmed
    b>Yellow fever, a mosquito-borne viral haemorrhagic fever, is one of the most lethal viral diseases. At present, an efficient vaccine for prevention is available, but may cause serious adverse events.
  73. Zengbe Acray P, Douba A, Traore Y, Dagnan S, Attoh Toure H, Ekra D. [Estimated operational costs of vaccination campaign to combat yellow fever in Abidjan]. Sante Publique. 2009;21:383-91 pubmed
    ..study was conducted with the main objective to assess the operational costs of a vaccination campaign against yellow fever organised and implemented in Abidjan from September 21st to October 2nd, 2001...
  74. Johansson M, Arana Vizcarrondo N, Biggerstaff B, Staples J. Incubation periods of Yellow fever virus. Am J Trop Med Hyg. 2010;83:183-8 pubmed publisher
    b>Yellow fever virus is a global health threat due to its endemicity in parts of Africa and South America where human infections occur in residents and travelers...
  75. de Almeida M, dos Santos E, da Cruz Cardoso J, da Fonseca D, Noll C, Silveira V, et al. Yellow fever outbreak affecting Alouatta populations in southern Brazil (Rio Grande do Sul State), 2008-2009. Am J Primatol. 2012;74:68-76 pubmed publisher
    The natural transmission cycle of Yellow Fever (YF) involves tree hole breeding mosquitoes and a wide array of nonhuman primates (NHP), including monkeys and apes...
  76. Lown B, Chen L, Wilson M, Sisson E, Gershman M, Yanni E, et al. Vaccine administration decision making: the case of yellow fever vaccine. Clin Infect Dis. 2012;55:837-43 pubmed publisher
    Providers must counsel travelers to yellow fever (YF)-endemic areas, although risk estimates of disease and vaccine serious adverse events (SAEs) may be imprecise...
  77. Pezzoli L, Conteh I, Kamara W, Gacic Dobo M, Ronveaux O, Perea W, et al. Intervene before leaving: clustered lot quality assurance sampling to monitor vaccination coverage at health district level before the end of a yellow fever and measles vaccination campaign in Sierra Leone in 2009. BMC Public Health. 2012;12:415 pubmed publisher
    In November 2009, Sierra Leone conducted a preventive yellow fever (YF) vaccination campaign targeting individuals aged nine months and older in six health districts...
  78. Monath T. Yellow fever vaccine. Expert Rev Vaccines. 2005;4:553-74 pubmed
    b>Yellow fever, a mosquito-borne viral hemorrhagic fever, is one of the most lethal diseases of humankind...
  79. Pugachev K, Guirakhoo F, Monath T. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005;18:387-94 pubmed
    ..We emphasize the need for stepped-up efforts to stop further spread and intensification of these infections worldwide...
  80. Huhn G, Brown J, Perea W, Berthe A, Otero H, Libeau G, et al. Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004. Vaccine. 2006;24:730-7 pubmed
    b>Yellow fever (YF) is a mosquito-borne vaccine-preventable disease with high mortality. In West Africa, low population immunity increases the risk of epidemic transmission...
  81. Codeço C, Luz P, Coelho F, Galvani A, Struchiner C. Vaccinating in disease-free regions: a vaccine model with application to yellow fever. J R Soc Interface. 2007;4:1119-25 pubmed
    ..the perspective of the susceptible individual, and results are shown in the context of the emergence of urban yellow fever in Brazil. The model decomposes the individual's choice about vaccinating or not into uncertain components...
  82. Sall A, Faye O, Diallo M, Firth C, Kitchen A, Holmes E. Yellow fever virus exhibits slower evolutionary dynamics than dengue virus. J Virol. 2010;84:765-72 pubmed publisher
    Although yellow fever has historically been one of the most important viral infections of humans, relatively little is known about the evolutionary processes that shape its genetic diversity...
  83. Julander J, Ennis J, Turner J, Morrey J. Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother. 2011;55:2067-73 pubmed publisher
    ..dose prior to virus infection, which resulted in a dose-responsive, protective effect in a hamster model of yellow fever virus (YFV) disease...
  84. Thibodeaux B, Garbino N, Liss N, Piper J, Schlesinger J, Blair C, et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res. 2012;94:1-8 pubmed publisher
    b>Yellow fever virus (YFV), a member of the genus Flavivirus, is a mosquito-borne virus found in tropical regions of Africa and South America that causes severe hepatic disease and death in humans...
  85. Yang G, Fattash I, Lee C, Liu K, Cavinder B. Birth of three stowaway-like MITE families via microhomology-mediated miniaturization of a Tc1/Mariner element in the yellow fever mosquito. Genome Biol Evol. 2013;5:1937-48 pubmed publisher
    ..Analyses of MITEs in the yellow fever mosquito identified its youngest MITE family, designated as Gnome, that contains at least 116 identical copies...
  86. Guirakhoo F, Zhang Z, Myers G, Johnson B, Pugachev K, Nichols R, et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004;78:9998-10008 pubmed publisher
    A chimeric yellow fever-dengue 1 (ChimeriVax-DEN1) virus was produced by the transfection of Vero cells with chimeric in vitro RNA transcripts...
  87. Barrett A, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209-29 pubmed
    b>Yellow fever virus (YFV) is the prototype member of the genus Flavivirus, a group of viruses that are transmitted between vertebrates by arthropod vectors...
  88. Adelman Z, Jasinskiene N, Onal S, Juhn J, Ashikyan A, Salampessy M, et al. nanos gene control DNA mediates developmentally regulated transposition in the yellow fever mosquito Aedes aegypti. Proc Natl Acad Sci U S A. 2007;104:9970-5 pubmed
    ..the successful use of the promoter and untranslated regions from the nanos (nos) orthologous gene of the yellow fever mosquito, Aedes aegypti, to control sex- and tissue-specific expression of exogenously derived mariner MosI ..
  89. Hansen I, Boudko D, Shiao S, Voronov D, Meleshkevitch E, Drake L, et al. AaCAT1 of the yellow fever mosquito, Aedes aegypti: a novel histidine-specific amino acid transporter from the SLC7 family. J Biol Chem. 2011;286:10803-13 pubmed publisher
    ..as essential upstream components of the nutrient signaling system in the fat body of fruit flies and the yellow fever mosquito, Aedes aegypti. However, the transport function of these proteins was unknown...
  90. Isoe J, Collins J, Badgandi H, Day W, Miesfeld R. Defects in coatomer protein I (COPI) transport cause blood feeding-induced mortality in Yellow Fever mosquitoes. Proc Natl Acad Sci U S A. 2011;108:E211-7 pubmed publisher
    ..processes beyond Golgi-endoplasmic reticulum retrograde protein trafficking, we disrupted COPI functions in the Yellow Fever mosquito Aedes aegypti to interfere with blood meal digestion...
  91. Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci. 2004;41:391-427 pubmed
    Despite the availability of a safe and efficacious vaccine, yellow fever (YF) remains a disease of significant public health importance, with an estimated 200,000 cases and 30,000 deaths annually...
  92. Quaresma J, Duarte M, Vasconcelos P. Midzonal lesions in yellow fever: a specific pattern of liver injury caused by direct virus action and in situ inflammatory response. Med Hypotheses. 2006;67:618-21 pubmed
    b>Yellow fever is an acute infectious, non-contagious disease characterized by intense vasculopathy and lesions in different organs...